SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp ($BATL) is experiencing a massive rally, fueled by reports of Iran threatening or closing the Strait of Hormuz, leading to anticipation of surging oil prices. The low-float energy stock is seeing intense community discussion around a potential short squeeze, driven by extremely high borrow fees and expectations of reaching $20-$50+.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid surging interest in photonics solutions for AI data centers, buoyed by recent institutional investment, a strategic partnership mention from Quantum Computing, and NVIDIA's broader sector validation. The community is actively discussing POET's optical interposer technology as a key enabler for next-generation high-speed interconnects and eagerly awaits major customer announcements.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as the Middle East conflict escalates, with reports of the Strait of Hormuz closure fueling expectations of soaring oil prices, though the community is actively discussing why INDO isn't matching the significant runs seen in peer oil stocks like BATL.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending following a significant stock drop, driven by cautious short-term guidance and recent leadership transitions, despite strong past earnings. This has ignited community debate, with some citing broader software sector pressures and growth concerns, while others see it as an exaggerated sell-off presenting a long-term buying opportunity given its AI and database platform.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following a positive earnings call that included accelerating satellite deployment plans, optimistic revenue growth guidance, and new partnerships with global telecom providers. The community is actively discussing the company's full funding for its constellation, expected additional announcements, and its emerging role in defense and space-based AI, prompting strong bullish sentiment against persistent skepticism.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as the first eVTOL company to achieve 100% FAA Means of Compliance acceptance, a pivotal regulatory milestone that bulls believe significantly de-risks its path to 2026 piloted operations, while community discussion continues around its Q4 loss and ongoing capital requirements.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending after a significant sell-off, driven by a Raymond James downgrade citing the recompeting of a $1.4 billion Space Force contract. Yet, many in the community perceive this as an overreaction and a buying opportunity, emphasizing other bullish analyst targets and robust demand for drones amid global conflicts.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid escalating geopolitical tensions driving increased demand for drone and autonomous defense solutions, with the community actively discussing potential short squeeze opportunities fueled by high volume and optimistic contract prospects.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending following its full-year 2025 earnings, which reported record revenue exceeding $100 million and significant profitability improvements, fueling community debate over its perceived undervaluation and ambitious $7B+ AI infrastructure pipeline, while skeptics point to past execution concerns and low institutional ownership.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending due to the Trump administration's ongoing military strikes against Iran, which has ignited polarized community discussions. While proponents hail the actions as vital for global security, critics widely dismiss it as an "illegal war" and a distraction from domestic issues and the "Epstein files," fueling intense debate and contributing to the stock's volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evofem Biosciences&nbsp;Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt&nbsp;Companies Targeting Closing in Fourth Quarter of 2024&nbsp;Mountain View, CA., September 24, 2024 —&nbsp;Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target,&nbsp;Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), today filed a&nbsp;<a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318604913&amp;type=HTML&amp;symbol=EVFM&amp;cdn=aa965ae7d29bd4fb48009ea93f2217c9&amp;companyName=Evofem+Biosciences+Inc.&amp;formType=PRE+14A&amp;dateFiled=2024-09-23">preliminary proxy</a> to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the “Merger Agreement”), with Aditxt and Adifem, Inc., a wholly-owned subsidiary of Aditxt (“Adifem”), pursuant to which, and on the terms and subject to the conditions thereof, Adifem will merge with and into Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt.Assuming the proposal is approved by Evofem stockholders and other closing conditions are met, including but not limited to the Company raising sufficient capital to fund its obligations at closing, the companies are targeting closing the transaction in the fourth quarter of 2024.&nbsp;No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.&nbsp;About Evofem Biosciences, Inc.Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexxi.com%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=Phexxi%26%23174%3B+%28lactic+acid%2C+citric+acid+and+potassium+bitartrate%29&amp;index=1&amp;md5=3e729597ceeb7cf85250cc4e87c1ad26">Phexxi&nbsp;®&nbsp;(lactic acid, citric acid and potassium bitartrate)&nbsp;</a>, is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.In July 2024, Evofem broadened its commercial offering with the acquisition of&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.solosec.com%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=2&amp;md5=f57d1d7baa215b526187a6b94e5c1456">SOLOSEC® (secnidazole) 2g oral granules&nbsp;</a>, an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose.&nbsp;Follow us on: LinkedIn:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevofem%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevofem&amp;index=3&amp;md5=d02dd9371f079a9ddf3d4b4c14e86d11">https://www.linkedin.com/company/evofem</a> Facebook:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FEvofem&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.facebook.com%2FEvofem&amp;index=4&amp;md5=7479074d1930b4c67c3da4c67775fd95">http://www.facebook.com/Evofem</a> X (f/k/a Twitter):&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FEvofem&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fx.com%2FEvofem&amp;index=5&amp;md5=27b4287d506408c08aa627eaa266acdc">https://x.com/Evofem</a>Phexxi&nbsp;®&nbsp;and SOLOSEC&nbsp;®&nbsp;are registered trademarks of Evofem Biosciences, Inc.&nbsp;About Aditxt, Inc.Aditxt, Inc.®&nbsp;is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.&nbsp;Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.For more information,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aditxt.com&amp;esheet=54117118&amp;newsitemid=20240904120561&amp;lan=en-US&amp;anchor=www.aditxt.com&amp;index=4&amp;md5=d821cbe54c4f57eac0b1c374c9688090">www.aditxt.com</a>.Follow us on:LinkedIn:&nbsp;<a href="https://www.linkedin.com/company/aditxt">https://www.linkedin.com/company/aditxt</a>&nbsp; Facebook:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Faditxtplatform%2F&amp;esheet=54117118&amp;newsitemid=20240904120561&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.facebook.com%2Faditxtplatform%2F&amp;index=6&amp;md5=44180bd3ab05184be51a0d6dec9d979b">https://www.facebook.com/aditxtplatform/</a>&nbsp;Forward-Looking StatementsCertain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&amp;A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.&nbsp;Additional Information and Where to Find ItThis communication may be deemed to be solicitation material in respect of the proposed transactions. In connection with the proposed transactions, a proxy statement of Evofem Biosciences, Inc. and other materials will be filed with the SEC. WE URGE INVESTORS TO READ THE PROXY STATEMENT AND THESE OTHER MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EVOFEM BIOSCIENCES, INC. AND THE PROPOSED TRANSACTIONS. Investors will be able to obtain free copies of the proxy statement (when available) as well as other filed documents containing information about Evofem Biosciences, Inc. on the SEC’s website at http://www.sec.gov. Free copies of Evofem Biosciences’ SEC filings are also available from Evofem Biosciences, Inc., 7770 Regents Road, Suite 113-618, San Diego, California 92122, Attention: Corporate Secretary.&nbsp;Participants in the SolicitationEvofem Biosciences and its executive officers, directors, other members of management, employees and Evofem Biosciences may be deemed, under SEC rules, to be participants in the solicitation of proxies from Evofem Biosciences’ stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of Evofem Biosciences is set forth in its definitive proxy statement for its special meeting. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed transactions.&nbsp;ContactAditxt, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mary O’Brien&nbsp;<a href="mailto:Mobrien@aditxt.com">Mobrien@aditxt.com</a>(516) 753-9933

Evofem Biosciences  Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Aditxt and Evofem file a preliminary proxy for stockholder approval of their merger, targeting a Q4 2024 closing. The merger aims to expand innovative women’s health solutions.

Aditxt and Evofem Seek Approval for Merger, Closing Expected Q4 2024

Equity

Aditxt and Evofem file for stockholder approval to finalize their merger in Q4 2024. The acquisition will position Evofem as a wholly owned Aditxt subsidiary, enhancing their women’s health portfolio.

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Evofem Biosciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

EVFM
Evofem Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EVFM News

EVFMEvofem Biosciences Inc